Theranos
Featuring Elizabeth Holmes
By 2015, Theranos was valued at roughly $9 billion on the promise of a machine that could run hundreds of tests from a single finger-prick of blood. There was one problem: the technology did not work, and Elizabeth Holmes knew it. The company kept promising a product that did not exist, and each time investors, partners, or patients showed up, it found a new way to fake the result rather than admit the gap.
Founders will recognize the trap long before they recognize the fraud. This case sits on the line between a stretch goal and a lie, and it sharpens the hardest judgment call a leader makes: when the honest answer is "this isn't working," but sunk cost, outside pressure, and your own identity all pull the other way. It is less about a villain than about the structural forces that make smart, ambitious people unable to stop. What pulls a company back from that edge is the part worth opening the app for.
Frequently asked questions
What was Theranos and what went wrong?
Theranos was a healthcare startup valued at roughly $9 billion by 2015 on the promise of a machine that could run hundreds of tests from a single finger-prick of blood. The problem was that the technology did not work, and founder Elizabeth Holmes knew it. The company kept promising a product that did not exist and faked results rather than admit the gap.
How much was Theranos worth and what did it claim to do?
Theranos was valued at roughly $9 billion by 2015 and claimed it could run hundreds of medical tests from a single finger-prick of blood. The technology never actually worked as promised. Each time investors, partners, or patients showed up, the company found a new way to fake the result.
Why is Theranos a case of escalation of commitment and sunk cost?
Theranos sat on the line between a stretch goal and a lie, and the structural forces of sunk cost, outside pressure, and Elizabeth Holmes's own identity all pulled against admitting the technology was not working. Rather than stopping when the honest answer was clearly no, the company doubled down and faked results. It is less a story about a villain than about what makes smart, ambitious people unable to stop.
What can founders learn from Theranos?
The lesson is to recognize when the honest answer is that something is not working, even as sunk cost, outside pressure, and your own identity pull the other way. The hardest judgment a leader makes is distinguishing a stretch goal from a lie before escalation takes over. CaseBook turns this into a move you apply to your own company, with an AI coach that reads your answer.